There are two main goals of antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis (AAV) treatment. The first goal is to bring the condition into remission by controlling active ...

A naturally occurring byproduct of liver metabolism—the ketone body, β-hydroxybutyrate (BHB)—can strengthen the fitness and antitumor activity of CAR T cells. The findings, reported on March 6, 2026 ...

The company plans to combine the CAR designs with its in-house delivery platform to advance its in vivo CAR-M therapies toward clinical studies.

Lyell Immunopharma, Inc. ( LYEL) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM EST ...

A Wisconsin bill would ban student cell phone use throughout the school day, expanding on a previous law that requires all school districts to approve a ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 1:10 PM ESTCompany ParticipantsSteven Harr - President, CEO ...

Obinutuzumab is a potent anti-B cell drug already approved to treat lupus nephritis, chronic lymphocytic leukemia, and follicular lymphoma. Therapies targeting B cells are perhaps the most effective ...

In August 2025, Edd Vieira, an engineer from Northamptonshire, England, was on vacation visiting his family in Portugal when he started feeling a “dull ache” on his left canine tooth. Days later, the ...

Enhancer hijacking emerges as a major “missing driver” mechanism in LBCL/PCN, enabling detection of non-chimeric oncogene activation such as IGL::BCL2, IGH::CCND2, and MAFA/MAFB rearrangements.

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across eight U.S. sites.

Our immune system relies on T cells to fight infections. But T cells don't just show up and react—first, they train, get a game plan, and coordinate their defenses in lymphoid organs. Researchers have ...

Why do diabetic wounds refuse to heal? A new scientific review highlights how disruptions in the timing and behavior of ...